Hyperviscosity syndrome (HVS) is a clinical emergency caused by pathologically increased blood viscosity, resulting in impaired microcirculatory flow. It classically presents with the triad of mucosal bleeding, visual disturbances, and neurological deficits. [1-3] The most common cause is elevated immunoglobulins (especially IgM in Waldenström macroglobulinemia), though elevated cellular components (RBCs, WBCs) can also be responsible. [1-2][4]
1. History
- Key HPI questions: Onset and progression of headache, blurred vision, epistaxis, gingival bleeding, confusion, dizziness, hearing changes, fatigue
- Symptom characterization: Symptoms are typically subacute and progressive; may present acutely with CNS hemorrhage or visual loss
- Timing/triggers: Often insidious; may be precipitated by dehydration or RBC transfusion (which adds to viscosity load) [5]
- Associated symptoms: Weight loss, anorexia, night sweats, paresthesias (neuropathy), dyspnea (CHF), menorrhagia [4][6]
- Important negatives: Absence of fever (helps distinguish from infection/leukostasis), absence of chest pain, no history of anticoagulant use
2. Alarm Features
- Acute altered mental status, stupor, or coma — suggests CNS hemorrhage or severe sludging [1][3]
- Sudden painless vision loss — retinal hemorrhage, central retinal vein occlusion [7]
- Massive epistaxis or GI hemorrhage unresponsive to local measures
- Acute heart failure/pulmonary edema — high-output failure from hypervolemia [8]
- Rapidly progressive renal failure — especially with cryoglobulinemia [9]
- Seizures or focal neurological deficits
3. Medications
- Rituximab caution: Can cause an IgM flare, worsening hyperviscosity. Per NCCN, rituximab should be held or preceded by plasmapheresis in patients with IgM ≥4,000 mg/dL [5]
- Avoid RBC transfusion before plasmapheresis — adds to viscosity load; transfuse only after plasmapheresis if indicated [5]
- Treatments:
- Acute: Plasmapheresis/therapeutic plasma exchange (TPE) — first-line emergent therapy [1][4-5]
- Definitive: Chemotherapy directed at underlying disease (e.g., bendamustine-rituximab, zanubrutinib for WM; bortezomib-based regimens for myeloma) [5]
- BTK inhibitors (zanubrutinib, ibrutinib): Used for WM; ibrutinib carries bleeding risk via platelet dysfunction [10]
- Avoid nephrotoxic agents if renal impairment is present
4. Diet
- Aggressive IV hydration in the acute setting to reduce viscosity and improve flow [11]
- No specific dietary triggers; however, dehydration worsens symptoms
- Long-term: Standard oncologic nutritional support as appropriate for underlying malignancy
5. Review of Systems
- Neurologic: Headache, dizziness, vertigo, ataxia, paresthesias, confusion, somnolence, seizures [4][6]
- Ophthalmologic: Blurred vision, diplopia, visual loss [6][9]
- ENT: Epistaxis, hearing loss, tinnitus [9]
- Hematologic: Easy bruising, gingival bleeding, GI bleeding, menorrhagia [4]
- Cardiovascular: Dyspnea, orthopnea, chest pain (CHF) [8]
- Constitutional: Fatigue, weight loss, night sweats, anorexia [6]
- Renal: Decreased urine output, hematuria
- Musculoskeletal: Bone pain (myeloma), arthralgias
6. Collateral History and Family History
- Prior diagnosis of monoclonal gammopathy, MGUS, WM, multiple myeloma, CLL, or polycythemia vera
- Family history of lymphoproliferative or plasma cell disorders
- History of autoimmune disease (RA, Sjögren's, IgG4-related disease) — polyclonal causes [12]
- Social history: HIV status (associated with polyclonal hypergammaglobulinemia) [12]
7. Risk Factors
- Waldenström macroglobulinemia — most common cause; symptomatic HVS in 10–30% of patients [4][13]
- Multiple myeloma — HVS in 2–6%, more common with IgA and IgG3 subtypes [4][14]
- Polycythemia vera — whole-blood hyperviscosity from elevated hematocrit [2][15]
- Hyperleukocytosis (AML, CML blast crisis) — WBC >100,000/μL [16-17]
- Cryoglobulinemia (type I > mixed) [9]
- Connective tissue diseases — RA (especially with Felty's syndrome), Sjögren's, SLE [8][12]
- IgG4-related disease, HIV, autoimmune lymphoproliferative syndrome [12]
- CXCR4 mutations in WM — associated with higher risk of symptomatic hyperviscosity [18]
8. Differential Diagnosis
- Leukostasis (hyperleukocytosis in acute leukemia) — similar CNS/pulmonary symptoms; distinguished by markedly elevated WBC [17]
- Thrombotic thrombocytopenic purpura (TTP) — neurologic symptoms + thrombocytopenia + MAHA
- Central retinal vein occlusion from other causes (hypertension, glaucoma, hypercoagulable states) [7][19]
- Stroke/TIA — focal deficits; imaging distinguishes
- Hypertensive emergency — similar fundoscopic findings; check BP
- Disseminated intravascular coagulation (DIC) — bleeding + coagulopathy
- Meningitis/encephalitis — headache + AMS; LP distinguishes
- Tumor lysis syndrome — in context of hematologic malignancy
9. Past Medical History
- Known plasma cell dyscrasia, lymphoproliferative disorder, or myeloproliferative neoplasm
- Prior episodes of HVS or plasmapheresis
- History of neuropathy, amyloidosis, cryoglobulinemia (IgM-related complications) [5]
- Chronic kidney disease (may worsen with HVS)
- Prior chemotherapy exposure (cumulative myelosuppressive toxicity) [5]
10. Physical Exam
- Vital signs: Hypertension (hypervolemia), tachycardia, hypoxia (if pulmonary involvement)
- HEENT: Oronasal mucosal bleeding (gingival oozing, epistaxis — most reliable early signs) [2]
- Fundoscopy (critical): Dilated, tortuous retinal veins; "venous sausaging"; dot-blot hemorrhages (peripheral → central); cotton-wool spots; papilledema; CRVO-like appearance [6][9]
- Neurologic: Altered mental status, ataxia, nystagmus, focal deficits, decreased hearing
- Cardiovascular: JVD, S3 gallop, peripheral edema (high-output CHF) [8]
- Lymphadenopathy, hepatosplenomegaly (underlying lymphoproliferative disease) [5]
- Skin: Purpura, ecchymoses, Raynaud phenomenon (cryoglobulinemia)
The following fundus photographs demonstrate the progressive severity of hyperviscosity-related retinopathy in WM, from normal (A) to dilated veins (B), peripheral hemorrhages (C), and severe central hemorrhages with papilledema and venous sausaging (D):
11. Lab Studies
- Serum viscosity: Normal 1.4–1.8 cP; symptoms typically appear at ≥4–5 cP, though retinal changes may occur as low as 2.1 cP. Viscosity measurement is not required to initiate emergent treatment if clinical suspicion is high [1][4][6][20]
- SPEP/SIFE: Identify monoclonal protein (M-spike)
- Quantitative immunoglobulins: IgM, IgG, IgA levels
- Symptomatic thresholds: IgM ≥3 g/dL, IgG ≥4 g/dL, IgA ≥6 g/dL [4]
- IgM >60 g/L carries 370-fold increased odds of symptomatic HVS [18]
- CBC with differential and peripheral smear: Anemia (common), rouleaux formation, leukocytosis (if leukostasis), thrombocytopenia
- CMP: BUN/creatinine (renal function), calcium, LFTs, albumin
- Coagulation studies: PT/INR, aPTT, fibrinogen; consider von Willebrand panel (acquired vWD) [5][10]
- LDH, beta-2 microglobulin, uric acid
- Cryocrit (if cryoglobulinemia suspected — must be drawn and transported warm) [5]
- ESR — markedly elevated
12. Imaging
- CT head without contrast: Urgent if altered mental status or focal neurological deficits — rule out intracranial hemorrhage
- CT chest/abdomen/pelvis: Evaluate for lymphadenopathy, hepatosplenomegaly (staging of underlying malignancy) [5]
- FDG-PET/CT: Useful for staging WM/lymphoma when possible [5]
- Echocardiography: If signs of heart failure
- Imaging is not required to diagnose HVS itself — diagnosis is clinical + laboratory
13. Special Tests
- Fundoscopic examination: Essential in all suspected cases; recommended annually if IgM >3,000 mg/dL [5-6]
- Bone marrow biopsy with immunohistochemistry/flow cytometry: Definitive for underlying diagnosis (WM, myeloma) [5]
- MYD88 L265P mutation testing (AS-PCR): Hallmark of WM, present in >95% of cases [5][13]
- CXCR4 mutation testing: Prognostic and predictive for BTK inhibitor response [5]
- Nerve conduction studies/EMG: If neuropathy suspected [5]
- Fat pad biopsy/Congo red staining: Rule out amyloidosis [5]
14. ECG
- No pathognomonic ECG findings for HVS
- ECG indicated to evaluate for:
- Ischemic changes (ST-segment depression/elevation) from impaired coronary microcirculation
- Signs of right heart strain if pulmonary hypertension develops
- Arrhythmias — atrial fibrillation (especially if on ibrutinib)
- Cardiac complications include congestive heart failure from hypervolemia and impaired microvascular perfusion [6][8]
15. Assessment
- HVS is a clinical diagnosis based on the classic triad (bleeding, visual changes, neurological symptoms) in the setting of known or suspected paraproteinemia or cellular hyperviscosity [1-3]
- Severity stratification:
- Mild: Fatigue, headache, peripheral retinal hemorrhages only
- Moderate: Epistaxis, blurred vision, dizziness
- Severe: AMS, coma, CNS hemorrhage, acute vision loss, CHF [6][14]
- Atypical presentations: Isolated hearing loss, renal failure (cryoglobulinemia), acquired vWD with bleeding [9][21]
- Complications: Retinal hemorrhage/CRVO, intracranial hemorrhage, stroke, renal failure, death (21% early mortality in elderly myeloma patients with HVS) [14]
16. Treatment Plan
Immediate stabilization
- IV fluid resuscitation — aggressive hydration to reduce viscosity
- Avoid RBC transfusion until after plasmapheresis [5]
Definitive acute treatment
- Plasmapheresis (therapeutic plasma exchange) — first-line for symptomatic HVS [1][4-5]
- Single plasma volume exchange (~3 L) typically produces dramatic improvement, especially for IgM (70–90% intravascular) [16]
- Reduces serum IgM by ~46% and viscosity by ~45% per session [22]
- Use blood warmers if cryoglobulin or cryoprecipitate present [5]
- Repeat as needed until symptoms resolve
- For whole-blood hyperviscosity (polycythemia vera): Phlebotomy to reduce hematocrit [1][15]
- For hyperleukocytosis: Leukapheresis (especially AML with WBC >100,000/μL) [16-17]
Disease-directed therapy (long-term)
- WM: Bendamustine-rituximab (6 cycles) or zanubrutinib (preferred first-line per NCCN); ibrutinib ± rituximab (other recommended) [5][13]
- Multiple myeloma: Bortezomib-based regimens ± immunomodulatory agents [14]
- Polyclonal causes: Treat underlying autoimmune/inflammatory disease (corticosteroids, rituximab, immunosuppressants) [12]
17. Disposition
- Admit all patients with symptomatic HVS — this is a medical emergency requiring plasmapheresis [1][3]
- ICU admission for: AMS/coma, active CNS or retinal hemorrhage, hemodynamic instability, acute heart failure
- Hematology/oncology consultation — essential for all cases to guide definitive therapy [3]
- Ophthalmology consultation — for fundoscopic evaluation and monitoring [5-6]
- Discharge only after symptoms resolve, viscosity is controlled, and definitive therapy plan is established
18. Follow Up / Return Precautions
- Follow-up timing: Close hematology follow-up within 1–2 weeks post-discharge; serial IgM and viscosity monitoring
- Annual retinal examination if IgM >3,000 mg/dL [5]
- Return precautions — instruct patients to seek immediate care for:
- New or worsening headache, confusion, or dizziness
- Any visual changes (blurred vision, floaters, vision loss)
- Nosebleeds, gum bleeding, or blood in stool/urine
- Shortness of breath or chest pain
- Weakness or numbness in extremities
- Expected course: Plasmapheresis provides temporary relief; recurrence is expected without disease-directed therapy. HVS in newly diagnosed myeloma carries a dismal prognosis (median OS 3.6 vs. 7.7 years). In WM, symptomatic hyperviscosity did not independently impact overall survival in one large study [14][18]
- Key counseling point: IgM level alone (without symptoms) should not drive re-treatment decisions — therapy is symptom-directed [5]
References
1. Acute Hyperviscosity: Syndromes and Management. — Gertz MA. Blood. 2018.
2. Hyperviscosity Syndrome. — Gertz MA, Kyle RA. Journal of Intensive Care Medicine. 1995.
3. Myeloproliferative Disorders and the Hyperviscosity Syndrome. — Adams BD, Baker R, Lopez JA, Spencer S. Hematology/Oncology Clinics of North America. 2010.
4. Hyperviscosity Syndrome in Plasma Cell Dyscrasias. — Mehta J, Singhal S. Seminars in Thrombosis and Hemostasis. 2003.
5. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. — Updated 2026-03-03. National Comprehensive Cancer Network.
6. Hyperviscosity-Related Retinopathy in Waldenström Macroglobulinemia. — Menke MN, Feke GT, McMeel JW, et al. Archives of Ophthalmology. 2006.
7. Central Retinal Vein Occlusion Due to Hyperviscosity Syndrome. — Chiang CC, Begley S, Henderson SO. The Journal of Emergency Medicine. 2000.
8. Hyperviscosity Syndrome in Rheumatoid Arthritis With Felty's Syndrome: Case Report and Review of the Literature. — Zakzook SI, Yunus MB, Mulconrey DS. Clinical Rheumatology. 2002.
9. The Cryoglobulinaemias. — Ramos-Casals M, Stone JH, Cid MC, Bosch X. Lancet. 2012.
10. Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation. — Brysland SA, Maqbool MG, Talaulikar D, Gardiner EE. Thrombosis and Haemostasis. 2022.
11. Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association. — Lui GK, Saidi A, Bhatt AB, et al. Circulation. 2017.
12. Polyclonal Hypergammaglobulinaemia: Assessment, Clinical Interpretation, and Management. — Zhao EJ, Cheng CV, Mattman A, Chen LYC. The Lancet. Haematology. 2021.
13. B-Cell Non-Hodgkin Lymphomas. — Silkenstedt E, Salles G, Campo E, Dreyling M. Lancet. 2024.
14. Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Study. — Debureaux PE, Harel S, Parquet N, et al. Frontiers in Immunology. 2022.
15. Hyperviscosity in Polycythemia Vera and Other Red Cell Abnormalities. — Kwaan HC, Wang J. Seminars in Thrombosis and Hemostasis. 2003.
16. Correction of Hyperviscosity by Apheresis. — Zarkovic M, Kwaan HC. Seminars in Thrombosis and Hemostasis. 2003.
17. Therapeutic Apheresis in Hyperleukocytosis and Hyperviscosity Syndrome. — Blum W, Porcu P. Seminars in Thrombosis and Hemostasis. 2007.
18. Serum IgM Level as Predictor of Symptomatic Hyperviscosity in Patients With Waldenström Macroglobulinaemia. — Gustine JN, Meid K, Dubeau T, et al. British Journal of Haematology. 2017.
19. Seeing Through Thick and Through Thin: Retinal Manifestations of Thrombophilic and Hyperviscosity Syndromes. — Rajagopal R, Apte RS. Survey of Ophthalmology. 2015.
20. Evaluation of Hyperviscosity in Monoclonal Gammopathies. — Crawford J, Cox EB, Cohen HJ. The American Journal of Medicine. 1985.
21. Diagnosis and Risk Stratification in Waldenström Macroglobulinemia. — Zanwar S, Kapoor P. Journal of the National Comprehensive Cancer Network : JNCCN. 2024.
22. Effect of Plasmapheresis on Hyperviscosity-Related Retinopathy and Retinal Hemodynamics in Patients With Waldenstrom's Macroglobulinemia. — Menke MN, Feke GT, McMeel JW, Treon SP. Investigative Ophthalmology & Visual Science. 2008.